Alluvi, known as BI 4744, offers a notable advance in obesity treatment. This dual agonist targeting both GLP-1 and glucose-dependent insulinotropic polypeptide receptors demonstrates compelling effectiveness in https://alluvi427949.digitollblog.com/profile